Edap Tms SA
NASDAQ:EDAP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.36
8.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Edap Tms SA
Edap Tms SA
Cash & Cash Equivalents
Edap Tms SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Edap Tms SA
NASDAQ:EDAP
|
Cash & Cash Equivalents
€43.5m
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
21%
|
|
|
Biomerieux SA
PAR:BIM
|
Cash & Cash Equivalents
€272.2m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
2%
|
CAGR 10-Years
11%
|
|
|
Carmat SA
PAR:ALCAR
|
Cash & Cash Equivalents
€11.4m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
4%
|
|
|
Biosynex SA
PAR:ALBIO
|
Cash & Cash Equivalents
€5.4m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
35%
|
CAGR 10-Years
18%
|
|
|
Visiomed Group SA
PAR:ALVMG
|
Cash & Cash Equivalents
€3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
36%
|
CAGR 10-Years
11%
|
|
|
Amplitude Surgical SA
PAR:AMPLI
|
Cash & Cash Equivalents
€29.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Edap Tms SA
Glance View
EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 227 full-time employees. The firm operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The firm invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The firm is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The firm is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.
See Also
What is Edap Tms SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
43.5m
EUR
Based on the financial report for Dec 31, 2023, Edap Tms SA's Cash & Cash Equivalents amounts to 43.5m EUR.
What is Edap Tms SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
21%
Over the last year, the Cash & Cash Equivalents growth was -31%. The average annual Cash & Cash Equivalents growth rates for Edap Tms SA have been 21% over the past three years , 17% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
